Genetics and function of the capsules of Burkholderia pseudomallei and their potential as therapeutic targets

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 265-271

  Reckseidler Zenteno, Shauna L ^a   Moore, Richard ^b   Woods, Donald E ^b  

^a ATHABASCA UNIVERSITY   (Canada)

^b Health Sciences Centre Calgary   (Canada)

Author keywords

Capsule; Environment; Melioidosis; Pathogenesis; Therapeutics

Indexed keywords

ABC TRANSPORTER; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIAL VACCINE; BURKHOLDERIA PSEUDOMALLEI VACCINE; GLYCOCONJUGATE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; POLYSACCHARIDE;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BURKHOLDERIA PSEUDOMALLEI; CARBOHYDRATE SYNTHESIS; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION; GENE IDENTIFICATION; GENE SEQUENCE; GROWTH INHIBITION; HUMAN; MELIOIDOSIS; NONHUMAN; PROTEIN TARGETING; SEQUENCE HOMOLOGY; VACCINE PRODUCTION; ANIMAL; CHEMISTRY; DRUG EFFECT; GENETICS; METABOLISM; MICROBIOLOGY; REVIEW;

ANIMALS; BURKHOLDERIA PSEUDOMALLEI; HUMANS; MELIOIDOSIS; POLYSACCHARIDES;

EID: 65449188288     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787316047     Document Type: Article

References (48)

1. Dance, D.A.B. Melioidosis: the tip of the iceberg? Clin. Microbiol. Rev. 1991, 4, 52-60.
2. Sanford, J.P.; In Principles and Practices of Infectious Diseases; G.L. Mandell, R.G. Douglas, Jr., and J.E. Bennett, Eds.; Churchill Livingstone: New York, 1995; pp. 2003-2009.
3. Cheng, A.C.; Currie, B.J. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev., 2005, 94, 383-416.
4. Reckseidler-Zenteno, S.L.; Ling, J.; Moore, R.A.; Woods, D.E. Recent research advances on the pathogenesis of melioidosis and glanders. Recent Res. Dev. Infect. Immun., 2003, 1, 187-202.
5. White, N.J.; Dance, D.A.B.; Chaowagul, W.; Wattanagoon, Y.; Wuthiekanun, V.; Pitakwatchara, N. Halving of mortality of severe melioidosis by ceftazidime. Lancet, 1989, 2, 697-701.
6. Perry, M.B.; MacLean, L.L.; Schollaardt, T.; Bryan, L.E.; Ho, M. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect Immun., 1995, 63, 3348-52.
7. Nimtz, M.; Wray, V.; Domke, T.; Brenneke, B.; Haussler, S.; Steinmetz, I. Structure of an acidic exopolysaccharide of Burkholderia pseudomallei. Eur. J. Biochem., 1997. 250, 608-16.
8. Karawara, K.; Dejsirilert, S; Ezaki, T. Characterization of three capsular polysaccharides produced by Burkholderia pseudomallei. FEMS Microbiol. Lett., 1998, 169, 283-7.
9. Reckseidler, S.L.; DeShazer, D.; Sokol, P.A.; Woods, D.E. Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect. Immun., 2001, 69, 34-44.
10. Isshiki, Y.; Matsuura, M.; Dejsirilert, S.; Ezaki, T.; Kawahara, K. Separation of 6-deoxy-heptan correction of 6-deoxy-heptane from a smooth-type lipopolysaccharide preparation of Burkholderia pseudomallei. FEMS Microbiol. Lett., 2001, 199, 21-5.
11. Reckseidler-Zenteno, S.L.; DeVinney, R.; Woods, D.E. The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect. Immun., 2005, 73, 1106-15.
12. DeShazer, D.; Waag, D.M.; Woods, D.E. Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant. Microb. Pathog. 2001, 30, 253-69.
13. Yu, Y.; Kim, H.S.; Chua, H.H.; Lin, C.H.; Sim, S.H.; Lin, D.; Derr, A.; Engels, R.; DeShazer, D.; Birren, B.; Nierman, W.C.; Tan, P. Genomic patterns of pathogen evolution revealed by comparison of Burkholderia pseudomallei, the causative agent of melioidosis, to avirulent Burkholderia thailandensis. BMC Microbiol., 2006, 6(46).
14. Reckseidler-Zenteno, S.L. Role of the Burkholderia pseudomallei Capsule, PhD. Thesis, University of Calgary, Canada, 2002.
15. Holden, M.T.; Titball,; R. W. Peacock, S.J.; Cerdeno-Tarraga, A.M.; Atkins, T.; Crossman, L.C.; Pitt, T.; Churcher, C.; Mungall, K.; Bentley, S.D.; Sebaihia, M.; Thomson, N.R.; Bason, N.; Beacham, I.R.; Brooks, K.; Brown, K.A.; Brown, N.F.; Challis, G.L.; Cherevach, I.; Chillingworth, T.; Cronin, A.; Crossett, B.; Davis, P.; DeShazer, D.; Feltwell, T.; Fraser, A.; Hance, Z.; Hauser, H.; Holroyd, S.; Jagels, K.; Keith, K.E.; Maddison, M.; Moule, S.; Price, C.; Quail, M.A.; Rabbinowitsch, E.; Rutherford, K.; Sanders, M.; Simmonds, M.; Songsivilai, S.; Stevens, K.; Tumapa, S.; Vesaratchavest, M.; Whitehead, S.; Yeats, C.; Barrell, B.G.; Oyston, P.C.; Parkhill, J. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 14240-5.
16. Steinmetz, I.;Rohde, M.; Brenneke, B. Purification and characterization of an exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. Infect. Immun., 1995, 63, 3959-65.
17. Liautard, J-P.; Jubier-Maurin, V.; Boigegrain, R-A.; Köhler, S. Antimicrobials: targeting virulence genes necessary for intracellular multiplication. Trends Microbiol., 2006, 14, 109-13.
18. Lee, Y.M.; Almqvist, F.; Hultgren, S.J. Targeting virulence for antimicrobial chemotherapy. Curr. Opin. Pharmacol., 2003, 3, 513-9.
19. Svensson, A.; Larsson, A.; Emtenas, H.; Hedenstrom, M.; Fex, T.; Hultgren, S.J.; Pinkner, J.S.; Almqvist, F.; Kihlberg, J. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem., 2001, 12, 915-8.
20. Garmory, H.S.; Titball, R.W. ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect. Immun., 2004, 72, 6757-63.
21. Hammond, S.M.; Claesson, A.; Jansson, A.M.; Larsson, L.G.; Pring, B.G.; Town, C.M.; Ekstrom, B. A new class of synthetic antibacterials acting on lipopolysaccharide biosynthesis. Nature, 1987, 327, 730-2.
22. Helm, J.S.; Hu, Y.; Chen, L.; Gross, B.; Walker, S. Identification of Active-Site Inhibitors of MurG Using a Generalizable, High-Throughput Glycosyltransferase Screen J. Am. Chem. Soc., 2003, 125, 11168-9.
23. Jones, S.M.; Ellis, J.F.; Russell, P.; Griffin, K.F.; Oyston, P. C. F. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J. Med. Microbiol., 2002, 51, 1055-62.
24. Nelson, M.; Prior, J.L.; Lever, M.S.; Jones, H.E.; Atkins, T.P.; Titball, R. W. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J. Med. Microbiol., 2004, 53, 1177-82.
25. Dintzis, R. Rational design of conjugate vaccines. Pediatr. Res., 1992, 32, 376-85.
26. Jennings, H. Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease. J. Infect. Dis., 1992, 165, S156-9.
27. Gold, R.; Lepow, M.L.; Goldschneider, I.; Gotschilich, E.C. Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J. Infect. Dis., 1977, 136, S31-5.
28. Jennings, H. Capsular polysaccharides as human vaccines. Advan. Charbohydr. Chem., 1983, 41, 155-208.
29. Robbins, J.B. Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry., 1978, 15, 839-54.
30. Hodgkin, P.D.; Basten, A. B cell activation, tolerance and antigen-presenting function. Curr. Opin. Immunol., 1995, 7, 121-9.
31. Mond, J.J.; Vos, Q.; Lees, A.; Snapper, C.M. T cell independent antigens. Curr. Opin. Immunol., 1995, 7, 349-54.
32. Cryz, S.J.; Jr., Sadoff, J.C.; Furer, E.; Germanier, R. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J. Infect. Dis., 1986, 154, 682-8.
33. Fattom, A.; Schneerson, R.; Watson, D.C.; Karakawa, W.W.; Fitzgerald, D.; Pastan, I.; Li, X.; Shiloach, J.; Bryla, D.A.; Robbins, J.B. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun., 1993, 61, 1023-32.
34. Insel, R.A.; Anderson, P. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J. Exp. Med., 1986, 163, 262-9.
35. Konadu, E.; Robbins, J.B.; Shiloach, J.; Bryla, D.B.; Szu, S.C. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect. Immun., 1994, 62, 5048-54.
36. Lett, E.; Gangloff, S.; Zimmerman, M.; Wachsmann, D.; Klein, J.-P. Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes. Infect. Immun., 1994, 62, 785-92.
37. Watson, D.C.; Robbins, J.B.; Szu, S.C. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect. Immun., 1992, 60, 4679-86.
38. Winter, A.J.; Rowe, G.E.; Duncan, J.R.; Eis, M.J.; Widom, J.; Ganem, B.; Morein, B. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infect. Immun., 1988, 56, 2808-17.
39. Braley-Mullen, H. Antigen requirements for priming of IgG producing B memory cells specific for Type III pneumococcal polysaccharide. Immunology., 1980, 40, 521-7.
40. Dintzis, R.Z.; Middleton, M.H.; Dintiz, H.M. Inhibition of anti-DNP antibody formation by high doses of DNP-polyacrylamide molecules; effects of hapten density and hapten valence. J. Immunol., 1985, 135, 423-7.
41. Dintzis, R.Z.; Middleton, M.H.; Dintiz, H.M. Studies on the immunogenicity and tolerogenicity of T-independent antigens. J. Immunol., 1983, 131, 2196-203.
42. Brett, P.J.; Woods, D.E. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect. Immun., 1996, 64, 2824-8.
43. Masignani, V.; Rappuoli, R; Pizza, M. Reverse vaccinology: a genome-based approach for vaccine development. Exp. Opin. Biol. Ther., 2002, 2, 895-905.
44. Pizza, M.; Scarlato, V.; Masignani, V.; Giuliani, M.M.; Arico, B.; Comanducci, M.; Jennings, G.T.; Baldi, L.;Bartolini, E.; Capecchi, B.; Galeotti, C.L.; Luzzi, E.; Manetti, R.; Marchetti, E.; Mora, M.; Nuti, S.; Ratti, G.; Santini, L.; Savino, S.; Scarselli, M.; Storni, E.; Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D.W. Hood, A.C. Jeffries, P.; Saunders, N.J.; Granoff, D.M.; Venter, J.C.; Moxon, E.R.; Grandi, G.; Rappuoli R. 2000. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science, 2000, 287, 1816-20.
45. Haeuw, J.F.; Libon, C.; Zanna, L.; Goetsch, L.; Champion, T.; Nguyen, T.N.; Bonnefoy, J.Y.; Corvaia, N.; Beck, A. Physicochemical characterization and immunogenicity studies of peptide and polysaccharide conjugate vaccines based on a promising new carrier protein, the recombinant Klebsiella pneumoniae OmpA. Dev. Biol. (Basel), 2000, 103, 245-50.
46. Potter, A.A.; Klashinsky, S.; Li, Y.; Frey, E.; Townsend, H.; Rogan, D.; Erickson, G.; Hinkley, S.; Klopfenstein, T.; Moxley, R.A.; Smith, D.R.; Finlay, B.B. Potter Vaccine, 2004, 22, 362-9.
47. Brown, J.S.; Ogunniyi, A.D.; Woodrow, M.C.; Holden, D.W.; Paton, J.C. Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection. Infect. Immun., 2001, 69, 6702-6.
48. Ogunniyi, A.D.; Folland, R.L.; Briles, S.K.; Hollingshead S.K.; Paton, J.C. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect. Immun., 2000, 68, 3028-33.